Charles River Labs appoints Reshema Kemps-Polanco to board; board expands to 12

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Board increased from 11 to 12; Kemps-Polanco appointed effective Jan 22, 2024.
She will serve on Compensation Committee and Strategic Planning and Capital Allocation Committee.
Received initial pro-rata equity award valued at $255,500 in RSUs and stock options.
Kemps-Polanco is EVP and Chief Commercial Officer of Novartis US with 25 years pharma experience.
No material transactions or arrangements with Kemps-Polanco requiring disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Reshema Kemps-Polanco

Director

CRL · CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Effective: 2024-01-22
Filed: January 24, 2024, 6:59 PM ET

Following the size increase of the Board, the Board filled the vacancy and appointed Ms. Reshema Kemps-Polanco to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Reshema Kemps-Polanco was appointed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..

Action: appointed
Role: Director

Exact text from the filing

Following the size increase of the Board, the Board filled the vacancy and appointed Ms. Reshema Kemps-Polanco to the Board.

View on SEC.gov

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filing history →

Source: SEC EDGAR

accession 0001100682-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.